Invesco Nasdaq Biotechnology ETF(IBBQ · ETF)
ETF quote, holdings, sector allocation, technicals, and options analytics.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $23.42 – $36.84
- YTD
- +23.62%
- IV Rank (30D)
- 56.78
- Straddle Price
- $1.83
- P/C Vol Ratio
- 0.00
Invesco Nasdaq Biotechnology ETF (IBBQ) ETF
- Exchange
- XNAS
- Inception
- 2021-06-11
- Has Options
- Yes
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2026-09-21 | 2026-09-25 | $0.2304 | CD |
| 2026-06-22 | 2026-06-26 | $0.0342 | CD |
| 2026-03-23 | 2026-03-27 | $0.0361 | CD |
| 2025-12-22 | 2025-12-26 | $0.0906 | CD |
| 2025-09-22 | 2025-09-26 | $0.0958 | CD |
| 2025-06-23 | 2025-06-27 | $0.0287 | CD |
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| GILD | Gilead Sciences Inc | 8.38% | Equity (US) | US |
| VRTX | Vertex Pharmaceuticals Inc | 7.65% | Equity (US) | US |
| AMGN | Amgen Inc | 7.62% | Equity (US) | US |
| REGN | Regeneron Pharmaceuticals Inc | 5.35% | Equity (US) | US |
| MRNA | Moderna Inc | 4.80% | Equity (US) | US |
| RVMD | Revolution Medicines Inc | 2.70% | Equity (US) | US |
| ILMN | Illumina Inc | 2.55% | Equity (US) | US |
| BIIB | Biogen Inc | 2.22% | Equity (US) | US |
| ALNY | Alnylam Pharmaceuticals Inc | 2.18% | Equity (US) | US |
| ROIV | Roivant Sciences Ltd | 1.76% | Equity (US) | — |
| INSM | Insmed Inc | 1.71% | Equity (US) | US |
| ARGX | Argenx SE | 1.70% | Cash/Money Market | — |
| RPRX | Royalty Pharma PLC | 1.70% | Equity (US) | — |
| INCY | Incyte Corp | 1.67% | Equity (US) | US |
| GH | Guardant Health Inc | 1.56% | Equity (US) | US |
| UTHR | United Therapeutics Corp | 1.39% | Equity (US) | US |
| VTRS | Viatris Inc | 1.30% | Equity (US) | US |
| MEDP | Medpace Holdings Inc | 1.13% | Equity (US) | US |
| JAZZ | Jazz Pharmaceuticals PLC | 1.01% | Equity (US) | — |
| NBIX | Neurocrine Biosciences Inc | 0.94% | Equity (US) | US |
| EXEL | Exelixis Inc | 0.93% | Equity (US) | US |
| ASND | Ascendis Pharma A/S | 0.91% | Equity (Foreign) | DK |
| TEM | Tempus AI Inc | 0.89% | Equity (US) | US |
| BBIO | Bridgebio Pharma Inc | 0.87% | Equity (US) | US |
| SMMT | Summit Therapeutics Inc | 0.87% | Equity (US) | US |
| ONC | BeOne Medicines Ltd | 0.86% | Cash/Money Market | — |
| HALO | Halozyme Therapeutics Inc | 0.84% | Equity (US) | US |
| BMRN | BioMarin Pharmaceutical Inc | 0.80% | Equity (US) | US |
| MDGL | Madrigal Pharmaceuticals Inc | 0.78% | Equity (US) | US |
| BNTX | BioNTech SE | 0.75% | Cash/Money Market | DE |
| TWST | Twist Bioscience Corp | 0.69% | Equity (US) | US |
| AXSM | Axsome Therapeutics Inc | 0.67% | Equity (US) | US |
| KRYS | Krystal Biotech Inc | 0.67% | Equity (US) | US |
| KYMR | Kymera Therapeutics Inc | 0.63% | Equity (US) | US |
| ARWR | Arrowhead Pharmaceuticals Inc | 0.62% | Equity (US) | US |
| AGPXX | Invesco Government & Agency Portfolio | 0.61% | Cash/Money Market | — |
| CYTK | Cytokinetics Inc | 0.60% | Equity (US) | US |
| IBRX | ImmunityBio Inc | 0.60% | Equity (US) | US |
| TXG | 10X Genomics Inc | 0.60% | Equity (US) | US |
| SNY | Sanofi SA | 0.59% | Cash/Money Market | FR |
| PTGX | Protagonist Therapeutics Inc | 0.59% | Equity (US) | US |
| CAI | Caris Life Sciences Inc | 0.59% | Equity (US) | US |
| PCVX | Vaxcyte Inc | 0.55% | Equity (US) | US |
| PRAX | Praxis Precision Medicines Inc | 0.52% | Equity (US) | US |
| SYRE | Spyre Therapeutics Inc | 0.51% | Equity (US) | US |
| IONS | Ionis Pharmaceuticals Inc | 0.48% | Equity (US) | US |
| IMVT | Immunovant Inc | 0.47% | Equity (US) | US |
| ALKS | Alkermes PLC | 0.47% | Equity (US) | — |
| RYTM | Rhythm Pharmaceuticals Inc | 0.45% | Equity (US) | US |
| AMRX | Amneal Pharmaceuticals Inc | 0.44% | Equity (US) | US |
| Category | Weight | Value | Positions |
|---|---|---|---|
| Short-term investment | 19.89% | $15.1M | 3 |
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -1.24% | 5 |
| Feb | -0.85% | 5 |
| Mar | -0.41% | 5 |
| Apr | -1.80% | 5 |
| May | -0.51% | 5 |
| Jun | +2.99% | 6 |
| Jul | +2.44% | 6 |
| Aug | +1.50% | 6 |
| Sep | -3.26% | 6 |
| Oct | +1.45% | 5 |
| Nov | +1.91% | 5 |
| Dec | +1.64% | 5 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL with confidence level (6/10)
Key Drivers:
- Bullish MACD signal
- Neutral RSI reading
- Low volatility regime
Primary Risks:
- Lack of clear technical trend direction
- Limited recent news sentiment impact
- High IV rank indicating low volatility
Investment Thesis: IBBQ presents a mixed bag, with both bullish and bearish signals present. The stock's low volatility regime and neutral RSI reading indicate a stable environment, while the MACD signal suggests potential for further gains.
Recent News Sentiment Impact: The recent news headlines have been generally neutral, with no significant impact on the stock price. However, the positive sentiment of headlines 4 and 5 may contribute to the stock's slight upward momentum.
Technical Analysis
Trend Direction:
- Short-term: NEUTRAL (no clear trend direction)
- Medium-term: BEARISH (price below SMAs)
- Long-term: BULLISH (price above SMA 200)
Support/Resistance Levels:
- Lower: $31.11 (Bollinger Band lower)
- Middle: $33.73 (SMA 20)
- Upper: $36.34 (Bollinger Band upper)
Momentum Signals: RSI: 68.79 (neutral), MACD signal line crossover above 0.25 (bullish), Bollinger Bands neutral
Volume Analysis:
- Volume SMA 20: 27316.75
- On-Balance Volume (OBV): 777767.39
- Volume Rate of Change: -67.63% (indicating low volume)
News & Sentiment Analysis
Recent Headlines Summary: Neutral news headlines from the past two weeks, with no significant impact on the stock price.
Sentiment Assessment: Aggregate sentiment is NEUTRAL, with no clear bias towards bullish or bearish news.
Catalyst Identification: No specific catalysts identified in recent news; however, the options market suggests a potential $2.00 move by expiration.
Market Narrative: The recent neutral news headlines and low volatility regime suggest a stable environment, while the MACD signal implies potential for further gains.
Risk & Volatility Assessment
Risk Metrics:
- Beta: 0.71 (low risk relative to SPY)
- Alpha: 0.32
- Correlation: 0.43
- Stock Volatility: 0.21
Options Market Signals: IV Rank: 13.1% (Low), Current IV: 28.5%, Expected Move: $2.00 (28 DTE)
Market Context & Positioning
Sector Performance: IBBQ is trading within the Nasdaq Biotech sector, which has been relatively strong.
Institutional Activity: Volume patterns suggest institutional interest, but no clear directional bias.
Correlation Analysis: IBBQ is positively correlated with its peers and the broader market.
Relative Valuation: Positioned within a trading range; no clear relative value assessment can be made.
Key Levels & Action Items
Critical Price Levels:
- Lower: $31.11 (Bollinger Band lower)
- Middle: $33.73 (SMA 20)
- Upper: $36.34 (Bollinger Band upper)
Breakout/Breakdown Levels: No clear breakout or breakdown levels identified.
Time-Sensitive Catalysts: No specific earnings dates or product launches scheduled in the near term.
Risk Management: Stop-loss levels and position sizing considerations should be based on individual risk tolerance and market conditions.
Additional Notes
Data Interpretation: RSI >70 = neutral, MACD signal line crossover above 0.25 = bullish
News Impact Assessment: Recent news headlines have been generally neutral; no significant impact on the stock price.
Risk Assessment Criteria: High Risk: Not applicable due to low volatility and stable environment.
Conclusion IBBQ presents a mixed bag, with both bullish and bearish signals present. The stock's low volatility regime and neutral RSI reading indicate a stable environment, while the MACD signal suggests potential for further gains. Investors should consider the recent news headlines and options market signals in their analysis, and position themselves accordingly based on individual risk tolerance and market conditions.
- IV Rank (30D)
- 56.78
- IV Rank (7D)
- 56.78
- Avg IV
- 56.3%
- Straddle (30D)
- $1.83
- Straddle (7D)
- $1.83
- P/C Volume
- 0.00
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
- Beta (1Y vs SPY)
- 0.74
- Correlation (SPY)
- 44.5%
- R²
- 0.20
- Ann. Volatility
- 21.5%
- SPY Volatility
- 13.0%
Low volatility - stock moves less than market
Click any bar to view the full quote for that stock.
| Symbol | Name | Weight % | Price | 1 Day | 1 Week | 1 Month |
|---|